Cantrixil is under clinical development by Vivesto and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cantrixil’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 17 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 17 Oct 2022 decreased Cantrixil’s LoA and PTSR for Ovarian Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cantrixil Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cantrixil overview

Cantrixil (Trx-1) is under development for the treatment of solid tumors including epithelial ovarian cancer, pancreatic cancer, primary peritoneal cancer and fallopian tube cancer. It is administered intra-peritonealy. Cantrixil is a construct of active drug candidate, TRXE-002, in a cyclodextrin shell. It is based on the super benzopyran drug technology and drug delivery system.

It is also under development for the treatment of ovarian cancer and is administered intravenously.

Vivesto overview

Vivesto, formerly Oasmia Pharmaceutical, is a pharmaceutical company, that develops, manufactures, markets and sells drugs for human and veterinary oncology. The company’s pipeline for human health includes Apealea (paclitaxel micellar) for treating adult patients with the first relapse of platinum-sensitive epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer; Docetaxel micellar, in development for advanced prostate cancer and Cantrixil in clinical development for late-stage ovarian cancer. Its pipeline for animal health includes paccal vet (paclitaxel) and doxophos vet (doxorubicin), currently under phase 2 stage, intended for the treatment of canine mastocytoma and lymphoma. Vivesto also carries out research for the development of next-generation technology platforms XR-18 and XR-19. The company operates through a research facility in Sweden. Vivesto is headquartered in Solna, Stockholm, Sweden.

Quick View Cantrixil LOA Data

Report Segments
  • Innovator
Drug Name
  • Cantrixil
Administration Pathway
  • Intraperitoneal
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Vivesto
  • Originator: Kazia Therapeutics
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.